D1 and D2 dopamine receptor-mediated mechanisms and behavioral supersensitivity. 1993

C Marin, and S A Parashos, and V Kapitzoglou-Logothetis, and A Peppe, and T N Chase
Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD 20892.

The contribution of D1 and D2 dopamine (DA) receptor mechanisms to the behavioral supersensitivity and receptor upregulation induced by chronic DA antagonist administration were compared. Rats received either the selective D1 DA receptor antagonist SCH23390, the selective D2 DA receptor antagonist raclopride, their combination, or haloperidol, a predominantly D2 antagonist, for 21 days. Equivalent cataleptogenic doses of all drugs and drug combinations were employed. Tolerance to the cataleptic response was observed only in the haloperidol-treated group. Apomorphine-induced stereotypies were significantly enhanced in SCH23390-, raclopride-, and haloperidol-treated rats. In contrast, coadministration of both SCH23390 and raclopride had no effect on apomorphine-induced stereotypy. These findings suggest that neuroleptics blocking in equal proportion D1 and D2 receptor sites might be less likely to induce tardive dyskinesia and drug tolerance than those acting selectively on one or the other of these receptor subtypes.

UI MeSH Term Description Entries
D008297 Male Males
D002375 Catalepsy A condition characterized by inactivity, decreased responsiveness to stimuli, and a tendency to maintain an immobile posture. The limbs tend to remain in whatever position they are placed (waxy flexibility). Catalepsy may be associated with PSYCHOTIC DISORDERS (e.g., SCHIZOPHRENIA, CATATONIC), nervous system drug toxicity, and other conditions. Cerea Flexibilitas,Flexibility, Waxy,Anochlesia,Anochlesias,Catalepsies,Flexibilitas, Cerea,Flexibilities, Waxy,Waxy Flexibilities,Waxy Flexibility
D006220 Haloperidol A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) Haldol
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001058 Apomorphine A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use. Apokinon,Apomorphin-Teclapharm,Apomorphine Chloride,Apomorphine Hydrochloride,Apomorphine Hydrochloride Anhydrous,Apomorphine Hydrochloride, Anhydrous,Apomorphine Hydrochloride, Hemihydrate,Britaject,Apomorphin Teclapharm
D001522 Behavior, Animal The observable response an animal makes to any situation. Autotomy Animal,Animal Behavior,Animal Behaviors
D001552 Benzazepines Compounds with BENZENE fused to AZEPINES.
D012457 Salicylamides Amides of salicylic acid.
D013239 Stereotyped Behavior Relatively invariant mode of behavior elicited or determined by a particular situation; may be verbal, postural, or expressive. Behavior, Stereotyped,Behaviors, Stereotyped,Stereotyped Behaviors
D015854 Up-Regulation A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Up-Regulation,Upregulation,Up-Regulation (Physiology),Up Regulation

Related Publications

C Marin, and S A Parashos, and V Kapitzoglou-Logothetis, and A Peppe, and T N Chase
February 1993, European journal of pharmacology,
C Marin, and S A Parashos, and V Kapitzoglou-Logothetis, and A Peppe, and T N Chase
August 1993, Proceedings of the National Academy of Sciences of the United States of America,
C Marin, and S A Parashos, and V Kapitzoglou-Logothetis, and A Peppe, and T N Chase
December 2002, Behavioural pharmacology,
C Marin, and S A Parashos, and V Kapitzoglou-Logothetis, and A Peppe, and T N Chase
June 1988, Clinical neuropharmacology,
C Marin, and S A Parashos, and V Kapitzoglou-Logothetis, and A Peppe, and T N Chase
September 1992, Synapse (New York, N.Y.),
C Marin, and S A Parashos, and V Kapitzoglou-Logothetis, and A Peppe, and T N Chase
March 1992, Synapse (New York, N.Y.),
C Marin, and S A Parashos, and V Kapitzoglou-Logothetis, and A Peppe, and T N Chase
June 1991, The Japanese journal of psychiatry and neurology,
C Marin, and S A Parashos, and V Kapitzoglou-Logothetis, and A Peppe, and T N Chase
November 1994, The Journal of pharmacology and experimental therapeutics,
C Marin, and S A Parashos, and V Kapitzoglou-Logothetis, and A Peppe, and T N Chase
September 1991, The Journal of pharmacology and experimental therapeutics,
C Marin, and S A Parashos, and V Kapitzoglou-Logothetis, and A Peppe, and T N Chase
May 1994, Synapse (New York, N.Y.),
Copied contents to your clipboard!